49 results
8-K
OPTN
OptiNose Inc
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
and an assessment of the safety and efficacy of 186 or 372 mcg twice daily (the 2 currently approved and marketed doses for XHANCE) over a 24-week … symptom was scored from 0-3. The volume of the ethmoid and maxillary sinuses occupied by disease was assessed using computer-assisted assessment
PRE 14A
5pyj1roea4ju0gojyg
21 Apr 23
Preliminary proxy
4:51pm
8-K
EX-1.1
idq qg8mk4tty7lbr
23 Nov 22
Optinose Announces Proposed Public Offering of Common Stock and Warrants
4:09pm
8-K
EX-10.1
a7npphi
21 Nov 22
Entry into a Material Definitive Agreement
6:16am
8-K/A
EX-99.1
28xku1
27 Sep 22
Departure of Directors or Certain Officers
4:38pm
8-K
EX-1.1
yknp fsivwdk8fsz9x
18 Nov 21
Optinose Announces Proposed Public Offering of Common Stock
12:20pm